Pipeline Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Pipeline Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference




Pipeline Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that Carmine Stengone, CEO of Pipeline, will present a company overview on Wednesday, April 19, 2023, at 3 pm ET at the 22nd Annual Needham Virtual Healthcare Conference. Company management will also participate in virtual one-on-one meetings with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – a SAD/MAD study and a PET study – in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Contacts

Company Contact:

Peter Slover

CFO

ir@pipeline-tx.com

Investor Contact:

Amy Conrad

amy@juniper-point.com